IL17A and psoriasis: In summary, the in vivo experiment validated the therapeutic potential of pab-miR396a-5p mimics in suppressing psoriasis by targeting HSP90 and inhibiting NF-κB, JAK-STAT, and IL-17 signaling (Fig. 10).